| Vol. 8.08 – 15 March, 2024 |
| |
|
|
| Scientists illuminated the causative contributor and potential mechanism of Kallistatin mediating hyperlipidemia to non-alcoholic fatty liver disease (NAFLD. 221 healthy control and 253 HLP subjects, 62 healthy control, and 44 non-alcoholic fatty liver disease subjects were enrolled. [Signal Transduction And Targeted Therapy] |
| |
|
|
PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors identified membrane-spanning 4-domains a7 (MS4A7) as a NAM-specific pathogenic factor that exacerbated MASH progression in mice. [Science Translational Medicine] |
|
|
|
| Researchers conducted whole-genome bisulfite sequencing on 331 intrahepatic cholangiocarcinoma (iCCAs) integrated with genetic, transcriptomic, and proteomic analyses, demonstrating the existence of four DNA methylation subtypes of iCCAs that exhibited unique post-operative clinical outcomes. [Cancer Research] |
|
|
|
| Scientists presented a strategy to generate liver organoids (LOs) containing Kupffer cells by recapitulating fetal liver hematopoiesis using human induced pluripotent stem cell-derived erythro-myeloid progenitors, the origin of tissue-resident macrophages, and hiPSC-derived LOs. [Cell Reports] |
|
|
|
| Investigators identified hepatic Snai1 and Snai2 as important transcriptional regulators for liver regeneration and fibrosis. Partial hepatectomy or CCl4 treatment increases occupancies of Snai1 and Snai2 on cyclin A2 and D1 promoters in the liver. [Cell Reports] |
|
|
|
| A new oncogenic circRNA, hsa_circ_0070039, was identified to be significantly upregulated in HCC through circRNA sequencing. As verified in 68 HCC samples, circNUP54 overexpression was correlated with aggressive cancerous behaviors and poor outcomes. [Cell Death & Disease] |
|
|
|
| Small nucleolar RNA host gene 5 (SNHG5) was found to be upregulated in activated HSCs in vitro and in primary HSCs isolated from fibrotic liver in vivo, and inhibition of SNHG5 suppressed HSC activation. [Communications Biology] |
|
|
|
| Investigators showed that AMPK activation led to YAP/TAZ inhibition and HSC inactivation in vitro, while the expression of a kinase-inactive mutant reversed these effects compared to wild type AMPKÉ‘1. [Scientific Reports] |
|
|
|
| Scientists investigated whether the profiles of circulating microRNAs packaged in extracellular vesicles were associated with responses to liver fibrosis treatments. [Scientific Reports] |
|
|
|
| Researchers examined the effects of C. lentillifera extract in ethyl acetate fraction on controlling lipid accumulation and lipid metabolism in HepG2 cells induced with oleic acid through the in vitro hepatic steatosis model. [Heliyon] |
|
|
|
|
|
| The authors provide an updated description of the pathophysiological events in which hepatic senescent cells are involved and their role in liver disease progression. [Nature Reviews Gastroenterology & Hepatology] |
|
|
|
| Investigators examine the contributions that hepatic organoids have made to three areas of liver research: as a source of cells and tissue for basic research, for drug discovery and drug safety testing, and for understanding disease pathobiology. [Liver International] |
|
|
|
|
| The US FDA has approved Madrigal Pharmaceuticals’ drug for a fatty liver disease known as non-alcoholic steatohepatitis (NASH), the first treatment to get the nod for the condition and opening up a multi-billion dollar opportunity. [Reuters] |
|
|
|
| The University of Chicago Medicine was the first health system in Illinois to treat patients with histotripsy, a new noninvasive technology that uses ultrasound energy to precisely destroy liver tumors. [OncLive] |
|
|
|
|
| April 22 – 25, 2024 Baltimore, Maryland, United States |
|
|
|
|
|
| Gilead Sciences, Inc. – San Mateo, California, United States |
|
|
|
| Foundation for Liver Research – London, England, United Kingdom |
|
|
|
| Ottawa Hospital Research Institute – Ottawa, Ontario, Canada |
|
|
|
| Virginia Commonwealth University – Richmond, Virginia, United States |
|
|
|
| Foundation for Liver Research – London, England, United Kingdom |
|
|
|
|